Hoba Therapeutics ApS: Financial statements 2018
CVR: 38231170
Source: annual report 2018, Danish Business Authority
01/04/2017 – 31/03/2018
Hoba Therapeutics ApS (CVR 38231170) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 485,419 and a net result of DKK -891,853. Equity in the 2018 report amounted to DKK 8,855,810. The solvency ratio was 85.3%.
- Gross Profit
- DKK 485,419
- Profit/Loss
- DKK -891,853
- Equity
- DKK 8,855,810
- Total Assets
- DKK 10,383,472
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of November 19, 2018, Steen Palle Petersen has joined the board of directors of Hoba Therapeutics ApS.
As of November 19, 2018, Lene Gerlach has left the board of directors of Hoba Therapeutics ApS.
About Hoba Therapeutics ApS
Hoba Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade. The board consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade (chair) and Gunnar Magnus Severus Modée Persson. The company's owners include Novo Holdings A/S, Danmarks Eksport- og Investeringsfond and EIC Fund. The company has 2 employees (2026). In 2026, the company reported a gross profit of DKK -61,710,701 and a net result of DKK -67,693,868 compared with DKK -43,008,287 the year before. Equity in the 2026 report amounted to DKK 1,143,899.
